<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63522">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278952</url>
  </required_header>
  <id_info>
    <org_study_id>Astellas ISR000990</org_study_id>
    <nct_id>NCT02278952</nct_id>
  </id_info>
  <brief_title>Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.</brief_title>
  <acronym>TANGELA</acronym>
  <official_title>Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Scientific &amp; Medical Affairs, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-interventional cohort study to assess a novel assay to detect excessive or
      insufficient immunosuppression from the drug tacrolimus in lung transplant recipients. The
      assay measures mean residual expression (MRE) of genes downstream of NFAT, a transcription
      factor regulated by tacrolimus. The investigators will assess whether MRE levels identify
      subjects at risk for rejection (insufficient immunosuppression) or infection (excessive
      immunosuppression).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acute rejection</measure>
    <time_frame>12 months</time_frame>
    <description>Frequency of acute cellular rejection episodes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infections</measure>
    <time_frame>12 months</time_frame>
    <description>Frequency of pulmonary or systemic infections</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Transplantation, Lung</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Lung transplant recipients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        The study will include lung allograft recipients within 2 months of transplantation at
        UCSF.

        Exclusion criteria:

        Subjects will be excluded who are (a) unable to provide consent of (b) if treating
        clinicians do not anticipate subject will start on tacrolimus. Recruitment and enrollment
        in this study are targeted equally between women and minorities and the study will not
        exclude and gender or racial/ethnic group. This study does not involve vulnerable
        populations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greenland John, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 26, 2016</lastchanged_date>
  <firstreceived_date>October 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
